Encapsulated cell technology: From research to market

Trends in Biotechnology

Volumn 20, Issue 9, 2002, Pages 382-387

  Orive, Gorka ^a   Hernández, Rosa María ^a   Gascón, Alicia R ^a   Igartua, Manoli ^a   Pedraz, José Luis ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; DISEASE CONTROL; INDUSTRY; MARKETING; SUSTAINABLE DEVELOPMENT;

BIOLOGICAL PRODUCTS;

BIOTECHNOLOGY;

ALGINIC ACID; ANTIPARKINSON AGENT; BETA GLUCURONIDASE; BLOOD CLOTTING FACTOR 9; CILIARY NEUROTROPHIC FACTOR; ENDOSTATIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH HORMONE; GUANIDINE DERIVATIVE; NEUBLASTIN; NEUROTROPHIC FACTOR; PEPTIDE; POLYLYSINE; POLYMETHYLENE CO GUANIDINE; SPHERAMINE; UNCLASSIFIED DRUG; UREASE; BIOMATERIAL; DRUG CARRIER;

BIOTECHNOLOGY;

ADOPTIVE IMMUNOTHERAPY; AMYOTROPHIC LATERAL SCLEROSIS; BIOREACTOR; BIOTECHNOLOGY; CANCER; CARDIOVASCULAR DISEASE; CELL ENCAPSULATION; CLINICAL RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVICE; DIABETES MELLITUS; ETHICS; GOVERNMENT; HEMOPHILIA; HUMAN; HUNTINGTON CHOREA; MARKET; MUCOPOLYSACCHARIDOSIS TYPE 7; MULTIPLE SCLEROSIS; NONHUMAN; PARKINSON DISEASE; POLICY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TREATMENT INDICATION; CELL TRANSPLANTATION; COMMERCIAL PHENOMENA; DELAYED RELEASE FORMULATION; DENMARK; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG SCREENING; ECONOMICS; FRANCE; LEGAL ASPECT; METHODOLOGY; MICROCAPSULE; UNITED STATES;

BIOTECHNOLOGY; CAPSULES; CELL TRANSPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; COMMERCE; DELAYED-ACTION PREPARATIONS; DENMARK; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION; DRUG INDUSTRY; FRANCE; HUMAN; SUPPORT, NON-U.S. GOV'T; UNITED STATES; HUMANS;

EID: 0036708087     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-7799(02)02037-1     Document Type: Review

References (37)

1. Cell-based therapies go live
2. Local endostatin treatment of gliomas administered by microencapsulated producer cells
3. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy
4. Cell factories for fighting cancer
5. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma
6. Tissue engineering
7. Regenerative medicine
8. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol
9. Islet transplantation in seven patients with type I diabetes mellitus using a glucorticoid-free immunosuppressive regimen
10. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation
11. Nanoporous biocapsules for the encapsulation of insulinoma cells: Biotransport and biocompatibility
12. Advances in bioartificial liver devices
13. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF family member neublastin/artemin
14. Infection of human cells by an endogenous retrovirus of pigs
15. Search for cross-species transmission of porcine endogeneous retrovirus in patients treated with living pig tissue
16. Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system
17. Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice
18. Call for moratorium on xenotransplants
19. Europe is urged to hold back on xenotransplant clinical trials
20. Bioartificial organs and acceptable risk
21. Cellular xenotransplantation
22. The trials of xenotransplantation
23. Objectively assessing bioartificial organs
24. Rationalizing the design of polymeric biomaterials
25. Controlled growth factor release from synthetic extracellular matrices
26. Intravital microscopy revelas novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells
27. Microencapsulated iNOS-expressing cells cause tumor suppression in mice
28. Delivery of human factor IX in mice by encapsulated recombinant myoblasts: A novel approach towards allogeneic gene therapy of hemophilia B
29. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease
30. GDNF reduces drug-induced rotational behaviour after medial forebrain bundle transection by a mechanism not involving striatal dopamine
31. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients
32. Treatment of a lysosomal storage disease, mucopolysacharidosis VII, with microencapsulated recombinant cells
33. Correction of the growth in Dwarf mice with nonautologous microencapsulated myoblasts, an alternative approach to somatic gene therapy
34. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats
35. An encapsulation system for the immunoisolation of pancreatic islets
36. Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression